Form 4: GeneDx Holdings Corp. Executive Kareem Saad Reports Stock Vesting
SEC Form 4 Filing
Kareem Saad, Chief Transformation Officer of GeneDx Holdings Corp., reports the vesting of restricted stock units.
Summary
- On March 9, 2024, Kareem Saad, the Chief Transformation Officer of GeneDx Holdings Corp., had 2,841 restricted stock units vest.
- These units convert into Class A Common Stock.
- Following the transaction, Mr. Saad directly owns 27,308 shares of Class A Common Stock and 31,249 restricted stock units.
- The restricted stock units vest in quarterly installments over a 4-year period starting March 9, 2023.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock vesting, neither particularly positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The vesting of restricted stock units may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/09/2023 | Commencement date for quarterly vesting of restricted stock units over a 4-year period |
| 03/09/2024 | Date of transaction: Vesting of 2,841 restricted stock units |
| 03/12/2024 | Date of report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.